TSS
JAZZ icon

Two Sigma Securities’s Jazz Pharmaceuticals JAZZ Stock Holding History

Two Sigma Securities’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-1,700
Closed -$211K – 3212
2023
Q2 		$211K Buy
+1,700
New +$229K ﹤0.01% 2174
2022
Q2 		– Sell
-3,600
Closed -$560K – 2553
2022
Q1 		$560K Buy
+3,600
New +$522K 0.02% 929

Other funds holding JAZZ

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

Two Sigma Securities's JAZZ Position: Q2 2026 in Review

Two Sigma Securities sold out of Jazz Pharmaceuticals (JAZZ) in Q2 2026, closing a stake of 1,065 shares — an estimated $201K sold.

Two Sigma Securities first reported a position in JAZZ in Q4 2016 and held it in 12 quarters. The position peaked at $411K in Q2 2024. 646 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.

  • Two Sigma Securities reported no remaining Jazz Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Two Sigma Securities sold 1,065 Jazz Pharmaceuticals shares in Q2 2026, an estimated $201K.
  • Two Sigma Securities first reported a position in Jazz Pharmaceuticals in Q4 2016 and held it in 12 quarters.
  • Two Sigma Securities's Jazz Pharmaceuticals position peaked at $411K in Q2 2024.
  • 646 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.

Based on Two Sigma Securities's 13F filing for Q2 2026, filed 14 Aug 2026.